Claims
- 1. A monoclonal antibody which is specifically reactive against B. anthracis.
- 2. The antibody of claim 1 which is non-reactive against B. cereus or B. thuringiensis.
- 3. The antibody of claim 1 which is an IgA, IgD, IgE, IgG or IgM.
- 4. The antibody of claim 1 which is reactive against a surface protein of B. anthracis.
- 5. The antibody of claim 4 wherein the surface protein is an EA1 protein.
- 6. The antibody of claim 1 which binds to SEQ ID NO. 1.
- 7. The antibody of claim 1 which is specifically reactive against B. anthracis spores.
- 8. The antibody of claim 1 which is specifically reactive against B. anthracis vegetative cells.
- 9. A hybridoma that produces the antibody of claim 1.
- 10. The hybridoma of claim 9 which is derived from an animal selected from the group consisting of cattle, chickens, goats, guinea pigs, horses, mice, pigs, primates, rabbits, rats and sheep.
- 11. A hybridoma deposited with ATCC and accorded accession number PTA-2632.
- 12. Antibody isolated from the hybridoma of claim 11.
- 13. An isolated antibody, or reactive portion thereof, directed to the EA1 protein of B. anthracis.
- 14. The antibody or reactive portion thereof of claim 13 which is a murine antibody; a rabbit antibody; a rat antibody; a genetically engineered antibody; a recombinant antibody; a humanized antibody; a polyclonal antibody or an affinity-purified antibody.
- 15. The antibody or reactive portion thereof of claim 13 which is an Fab or Fv fragment.
- 16. A diagnostic kit comprising an antibody that is specifically reactive against spores or vegetative cells of B. anthracis, B. thuringiensis or B. cereus.
- 17. The diagnostic kit of claim 16 which incorporates a colloidal particle based lateral flow detection system.
- 18. The diagnostic kit of claim 16 which incorporates a detection system selected from the group consisting of a carbon based lateral flow system; a fluorescent based assay system, a chemiluminescent system, an up converting phosphors system, a refractive indexed based detection system, a magnetic bead or latex bead system, and a micro array system.
- 19. A diagnostic kit comprising an antibody that is specifically reactive against spores of B. anthracis and not B. thuringiensis, and incorporates a colloidal particle based lateral flow detection system.
- 20. A diagnostic kit comprising an antibody that is specifically reactive against spores of B. thuringiensis and not B. anthrancis, and incorporates a colloidal particle based lateral flow detection system.
- 21. A method for producing a species-specific monoclonal antibody to one species of Bacillus comprising:
immunizing a host with a preparation of said one species of Bacillus; boosting said host with another preparation of an antigenically similar, but not identical, species of Bacillus; boosting said host with said preparation of said one species; fusing antibody-producing cells from the host with immortalized cells; and selecting a hybridoma that produces the species-specific monoclonal antibody to said one species of Bacillus.
- 22. The method of claim 21 wherein the one species of Bacillus is B. cereus, B. thuringiensis or B. anthracis.
- 23. The method of claim 21 wherein the other antigenically similar species of Bacillus is B. cereus, B. thuringiensis, B. anthracis or combinations thereof.
- 24. The method of claim 21 wherein the one species of Bacillus is B. anthracis and the other antigenically similar species of Bacillus is B. cereus or B. thuringiensis.
- 25. The method of claim 21 wherein the one species of Bacillus is B. thuringiensis and the other antigenically similar species of Bacillus is B. cereus or B. anthracis.
- 26. The method of claim 21 wherein the preparation of said one species comprises spores, vegetative cells or combinations thereof.
- 27. The method of claim 21 wherein the preparation of said other antigenically similar species comprises spores, vegetative cells or combinations thereof.
- 28. The method of claim 21 wherein the species-specific monoclonal antibody is selected from the group consisting of IgA, IgE, IgG, IgM and associated sub-types.
- 29. The method of claim 21 wherein the host is selected from the group consisting of mice, rats, horses, cattle, chickens, sheep, goats, pigs and primates.
- 30. The method of claim 21 wherein boosting with the antigenically similar species is performed about seven days prior to fusing.
- 31. The method of claim 21 wherein boosting with B. anthracis is performed about three days prior to fusing.
- 32. A species-specific monoclonal antibody to spores of B. anthracis made by the method of claim 21.
- 33. A diagnostic kit comprising the antibody of claim 32.
- 34. A hybridoma that expresses the antibody of claim 32.
- 35. An antibody which is specifically reactive against B. thuringiensis and non-reactive against B. cereus or B. anthracis.
- 36. An antibody which is specifically reactive against B. cereus and non-reactive against B. anthracis or B. thuringiensis.
- 37. An isolated or recombinant antigen, or antigenically active portions thereof, comprising an EA1 protein of the surface layer of B. anthracis.
- 38. A pharmaceutical composition comprising the antigen, or active portions hereof, of claim 37 and a pharmaceutically acceptable carrier.
- 39. A method of using the antigen, or active portions thereof, of claim 37 as the target for an immunological detection system for B. anthracis.
- 40. A vaccine against B. anthracis comprising a therapeutically effective amount of the antigen, or active portions thereof, of claim 37.
- 41. A method for vaccinating against B. anthracis comprising administering the therapeutically effective amount of the vaccine of claim 40 to a patient.
- 42. A therapeutic agent comprising antibodies to the EA1 protein.
- 43. A method for treating, preventing or controlling B. anthracis infection comprising administering an effective amount of the therapeutic agent of claim 42 to a patient.
REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional patent application Ser. No. 60/200,505, entitled “Anthrax Specific Antibodies,” filed Apr. 28, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60200505 |
Apr 2000 |
US |